Cargando…

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer

ALK gene rearrangement was observed in 3%–5% of non-small cell lung cancer patients, and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple ALK-TKI resistance mutations have been identified from the patients, and several compound mutations, such as I1171N + F1174I o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mizuta, Hayato, Okada, Koutaroh, Araki, Mitsugu, Adachi, Jun, Takemoto, Ai, Kutkowska, Justyna, Maruyama, Kohei, Yanagitani, Noriko, Oh-hara, Tomoko, Watanabe, Kana, Tamai, Keiichi, Friboulet, Luc, Katayama, Kazuhiro, Ma, Biao, Sasakura, Yoko, Sagae, Yukari, Kukimoto-Niino, Mutsuko, Shirouzu, Mikako, Takagi, Satoshi, Simizu, Siro, Nishio, Makoto, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904790/ https://www.ncbi.nlm.nih.gov/pubmed/33627640 http://dx.doi.org/10.1038/s41467-021-21396-w

Ejemplares similares

Structural Insight into TNIK Inhibition
por: Kukimoto-Niino, Mutsuko, et al.
Publicado: (2022)

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
por: Shimizu, Yuki, et al.
Publicado: (2022)

Cell-permeable Carboxyl-terminal p27(Kip1) Peptide Exhibits Anti-tumor Activity by Inhibiting Pim-1 Kinase
por: Morishita, Daisuke, et al.
Publicado: (2011)

Cell-free synthesis of functional antibody fragments to provide a structural basis for antibody–antigen interaction
por: Matsuda, Takayoshi, et al.
Publicado: (2018)

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
por: Okada, Koutaroh, et al.
Publicado: (2019)

Structural Basis for the Inhibition of Cyclin G‐Associated Kinase by Gefitinib
por: Ohbayashi, Naomi, et al.
Publicado: (2018)

A conserved PI(4,5)P2–binding domain is critical for immune regulatory function of DOCK8
por: Sakurai, Tetsuya, et al.
Publicado: (2021)

Granzyme A Stimulates pDCs to Promote Adaptive Immunity via Induction of Type I IFN
por: Shimizu, Kanako, et al.
Publicado: (2019)

Reduced efficacy of a Src kinase inhibitor in crowded protein solution
por: Kasahara, Kento, et al.
Publicado: (2021)

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase
por: Liang, Shuai, et al.
Publicado: (2021)

TNIK inhibition abrogates colorectal cancer stemness
por: Masuda, Mari, et al.
Publicado: (2016)

Targeting Ras-binding domain of ELMO1 by computational nanobody design
por: Tam, Chunlai, et al.
Publicado: (2023)

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer
por: Takahashi, Ken, et al.
Publicado: (2020)

Cryo-EM structure of the human ELMO1-DOCK5-Rac1 complex
por: Kukimoto-Niino, Mutsuko, et al.
Publicado: (2021)

Hydrophobic interactions at subsite S1′ of human dipeptidyl peptidase IV contribute significantly to the inhibitory effect of tripeptides
por: Araki, Mitsugu, et al.
Publicado: (2020)

Direct homophilic interaction of LAMP2A with the two-domain architecture revealed by site-directed photo-crosslinks and steric hindrances in mammalian cells
por: Terasawa, Kazue, et al.
Publicado: (2021)

Exploring ligand binding pathways on proteins using hypersound-accelerated molecular dynamics
por: Araki, Mitsugu, et al.
Publicado: (2021)

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)

ErbB4‐mediated regulation of vasculogenic mimicry capability in breast cancer cells
por: Kawahara, Ryota, et al.
Publicado: (2022)

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
por: Gong, Bo, et al.
Publicado: (2019)

N-glycosylation of R-spondin1 at Asn137 negatively regulates its secretion and Wnt/β-catenin signaling-enhancing activity
por: TSUCHIYA, MIYU, et al.
Publicado: (2016)

Integrin β1 is an essential factor in vasculogenic mimicry of human cancer cells
por: Kawahara, Ryota, et al.
Publicado: (2018)

Bcl‐2 Inhibits Calcineurin‐mediated Fas Ligand Expression in Antitumor Drug‐treated Baby Hamster Kidney Cells
por: Simizu, Siro, et al.
Publicado: (2000)

Tyrosinase suppresses vasculogenic mimicry in human melanoma cells
por: Kamo, Hiroki, et al.
Publicado: (2022)

Methionine aminopeptidase-2 is a pivotal regulator of vasculogenic mimicry
por: Shimizu, Shota, et al.
Publicado: (2022)

The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain
por: Chen, Wei, et al.
Publicado: (2020)

A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan
por: Goto, Yasushi, et al.
Publicado: (2023)

Dimerization of DOCK2 Is Essential for DOCK2-Mediated Rac Activation and Lymphocyte Migration
por: Terasawa, Masao, et al.
Publicado: (2012)

Gilteritinib (XOSPATA®) in Turkey: Early Access Program Results
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

Involvement of conserved tryptophan residues for secretion of TIMP-2
por: UKAJI, TAMAMI, et al.
Publicado: (2014)

Identification of DPY19L3 as the C-mannosyltransferase of R-spondin1 in human cells
por: Niwa, Yuki, et al.
Publicado: (2016)

Cell-dependent regulation of vasculogenic mimicry by carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1)
por: Hayashi, Soichiro, et al.
Publicado: (2020)

Involvement of DPY19L3 in Myogenic Differentiation of C2C12 Myoblasts
por: Mori, Kento, et al.
Publicado: (2021)

Correction: Mori et al. Involvement of DPY19L3 in Myogenic Differentiation of C2C12 Myoblasts. Molecules 2021, 26, 5685
por: Mori, Kento, et al.
Publicado: (2022)

PB1897: GILTERITINIB IN TURKEY: EARLY ACCESS PROGRAM RESULTS
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2023)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Yoshizawa, Takahiro, et al.
Publicado: (2021)

Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
por: Katagiri, Seiichiro, et al.
Publicado: (2023)

Lorlatinib for non-small cell lung cancer
Publicado: (2020)

Evaluation and Management of Dyslipidemia in Patients Treated with Lorlatinib
por: Blais, Normand, et al.
Publicado: (2021)

Podcast on the Management of Adverse Events Associated with Lorlatinib
por: Bauer, Todd M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mgql68ek0q57udlmleodp436l1